Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Background Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic
lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase …

Abstract Background Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have
transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic …

Mantle-Cell Lymphoma Accounting for 5 to 7% of all lymphomas, mantle-cell lymphoma has
historically been associated with a poor outcome, but survival is improving. The …

Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for
B-cell–driven malignancies. However, approved covalent BTK inhibitors (cBTKis) are …

Background Patients with relapsed or refractory chronic lymphocytic leukaemia or small
lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) …

Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5× 10 9/L
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …

Background Both continuous therapy with acalabrutinib and fixed-duration therapy with
venetoclax–obinutuzumab are effective for previously untreated chronic lymphocytic …

PURPOSE Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase
inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent …